Patents by Inventor Yat Sun Or

Yat Sun Or has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS
    Publication number: 20220041652
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 21, 2021
    Publication date: February 10, 2022
    Inventors: Joseph D. Panarese, Dexter Davis, Nathaniel Thomas Kenton, Samuel Bartlett, Sean M. Rafferty, Yat Sun Or
  • FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS
    Publication number: 20220033383
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 19, 2021
    Publication date: February 3, 2022
    Inventors: Joseph D. Panarese, Dexter Davis, Nathaniel Thomas Kenton, Samuel Bartlett, Sean M. Rafferty, Yat Sun Or
  • Functionalized heterocycles as antiviral agents
    Patent number: 11236108
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: February 1, 2022
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Joseph D. Panarese, Nathaniel Thomas Kenton, Samuel Bartlett, Dexter Davis, Yat Sun Or
  • Hepatitis B antiviral agents
    Patent number: 11236111
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: February 1, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yao-Ling Qiu, Xuri Gao, Xiaowen Peng, Wei Li, Jorden Kass, Hui Cao, Byung-Chul Suh, Jiajun Zhang, Yat Sun Or
  • DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS
    Publication number: 20220016112
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: July 6, 2021
    Publication date: January 20, 2022
    Inventors: Jianming Yu, In Jong Kim, Yat Sun Or
  • Functionalized heterocycles as antiviral agents
    Patent number: 11198693
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: December 14, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joseph Panarese, Dexter Davis, Samuel Bartlett, Katherine Chong, Nathaniel Kenton, Yat Sun Or
  • Heterocyclic compounds as RSV inhibitors
    Patent number: 11179400
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: November 23, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Jianming Yu, In Jong Kim
  • FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS
    Publication number: 20210292320
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: March 15, 2021
    Publication date: September 23, 2021
    Inventors: Joseph D. Panarese, Dexter Davis, Nathaniel Thomas Kenton, Samuel Bartlett, Yat Sun Or
  • HEPATITIS B ANTIVIRAL AGENTS
    Publication number: 20210283077
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: February 3, 2021
    Publication date: September 16, 2021
    Inventors: Yao-Ling Qiu, Xuri Gao, Jorden Kass, Hui Cao, Wei Li, Xiaowen Peng, Byung-Chul Suh, Yat Sun Or
  • Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof
    Publication number: 20210261600
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 26, 2021
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Jiang Long, Peng Dai, Xuechao Xing, Jing He
  • Heterocyclic compounds as RSV inhibitors
    Patent number: 11091501
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 17, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: In Jong Kim, Jianming Yu, Joseph Panarese, Kevin McGrath, Solymar Negretti-Emmanuelli, Thomas P. Blaisdell, Brian C. Shook, Yat Sun Or
  • HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS
    Publication number: 20210238188
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 5, 2021
    Inventors: Yong He, Xuechao Xing, Guoqiang Wang, Ruichao Shen, Brett Granger, Jiang Long, Yat Sun Or
  • HEPATITIS B ANTIVIRAL AGENTS
    Publication number: 20210230176
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 7, 2021
    Publication date: July 29, 2021
    Inventors: Yao-Ling Qiu, Xuri Gao, Wei Li, Hui Cao, Meizhong Jin, Jorden Kass, Xiaowen Peng, Yat Sun Or
  • Substituted heterocycles as antiviral agents
    Patent number: 11058678
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 13, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joseph Panarese, Samuel Bartlett, Katherine Chong, Yat Sun Or
  • Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
    Patent number: 11040998
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: June 22, 2021
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
  • Isoxazole analogs as FXR agonists and methods of use thereof
    Patent number: 11034684
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: June 15, 2021
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Jun Ma, Guoqiang Wang, Bin Wang, Xuechao Xing, Ruichao Shen, Jing He, Yat Sun Or
  • Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 11008304
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: May 18, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Brett Granger, Jing He, Xuechao Xing, Yong He, Jiang Long, Jun Ma, Bin Wang, Yat Sun Or
  • Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 10988458
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: April 27, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
    Publication number: 20210115060
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: October 29, 2020
    Publication date: April 22, 2021
    Inventors: Joseph Panarese, Samuel Bartlett, Dexter Davis, Katherine Chong, Yat Sun Or
  • Heterocyclic compounds as RSV inhibitors
    Patent number: 10975094
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: April 13, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jianming Yu, Solymar Negretti-Emmanuelli, In Jong Kim, Yat Sun Or